DC-CIK免疫治疗联合化疗对肺癌患者近远期疗效的影响  

Effect of DC-CIK Immunotherapy Combined with Chemotherapy on Short-Term and Long-Term Efficacy of Patients with Lung Cancer

作　　者：韦凤 WEI Feng(Chongqing People's Hospital,Chongqing,China 401122)

机构地区：[1]重庆市人民医院,重庆401122

出　　处：《中国药业》2022年第S02期17-19,共3页China Pharmaceuticals

摘　　要：目的探讨自体树突状细胞(DC)-细胞因子活化杀伤细胞(CIK)免疫治疗联合化学治疗(简称化疗)对肺癌患者近远期疗效的影响。方法选取医院2018年9月至2020年8月收治的肺癌患者60例,按治疗方式的不同分为对照组和观察组,各30例。两组患者均采取常规化疗方案治疗,观察组患者加用DC-CIK免疫治疗。结果观察组患者的客观缓解率为73.33%,显著高于对照组的46.67%(P<0.05);治疗后,观察组患者的生活质量评分显著更高,临床症状评分显著更低(P<0.05);观察组患者的中位生存期显著长于对照组(P<0.05);观察组患者1年生存率为80.00%,显著高于对照组的50.00(P<0.05)。结论DC-CIK免疫治疗联合化疗可提高肺癌患者的近远期疗效,有助于改善患者的疾病症状和机体免疫功能,提升整体生活质量。Objective To investigate the effect of autologous dendritic cells(DC)-cytokine activated killer cells(CIK)immunotherapy combined with chemotherapy on the short-term and long-term efficacy of patients with lung cancer.Methods A total of 60 patients with lung cancer admitted to the hospital from September 2018 to August 2020 were selected and divided into the control group and the observation group according to the different treatment methods,with 30 cases in each group.The patients in both groups were treated with conventional chemotherapy,and the patients in the observation group were treated with DC-CIK immunotherapy on this basis.Results The objective remission rate in the observation group was 73.33%,which was significantly higher than 46.67%in the control group(P<0.05).After treatment,the quality of life score in the observation group was significantly higher than those in the control group,while the clinical symptom score in the observation group was significantly lower than those in the control group(P<0.05).The median survival time in the observation group was significantly longer than that in the control group(P<0.05).The 1-year survival rate in the observation group was 80.00%,which was significantly higher than 50.00%in the control group(P<0.05).Conclusion DC-CIK immunotherapy combined with chemotherapy can improve the short-term and long-term efficacy of patients with lung cancer,improve the disease symptoms,immune function,and the overall quality of life.

关 键 词：肺癌 自体树突状细胞-细胞因子活化杀伤细胞免疫治疗 化学治疗 疾病缓解率 远期生存率 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]